People · Operator

Ron Bache

Named in public records as an officer, director or promoter · active 2010–2014 · Biotechnology

1
Companies
3
Filings
$49.5M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Aquesys IncBiotechnologySeries B$49.5M$1.2B2010
Operator network

Ron Bache at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

David Milne · 7 companies · 1 sharedDavid MilneRyan Schwarz · 7 companies · 1 sharedRyan SchwarzAnthony Lando · 6 companies · 1 sharedAnthony LandoJuliet Tammenoms Bakker · 5 companies · 1 sharedJuliet Tammenoms …Steven Waite · 4 companies · 1 sharedSteven WaiteAndrew Corley · 2 companies · 1 sharedAndrew CorleyMichael Tyson · 2 companies · 1 sharedMichael TysonDavid Tammenoms Milne · 1 companies · 1 sharedDavid Tammenoms M…Edward Tammenoms Peterson · 1 companies · 1 sharedEdward Tammenoms …Gregory Tammenoms Grunberg · 1 companies · 1 sharedGregory Tammenoms…Julie Bakker · 1 companies · 1 sharedJulie BakkerMichael Lee Tyson · 1 companies · 1 sharedMichael Lee TysonRyan Tammenoms Schwarz · 1 companies · 1 sharedRyan Tammenoms Sc…Steven Tammenoms Waite · 1 companies · 1 sharedSteven Tammenoms …Aquesys Inc · $49.5M raisedAquesys IncRon BacheRB
Ron Bache Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Ron Bache on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Ryan Schwarz17
David Milne17
Anthony Lando16
Juliet Tammenoms Bakker15
Steven Waite14
Michael Tyson12
Andrew Corley12
Gregory Tammenoms Grunberg11
Michael Lee Tyson11
David Tammenoms Milne11
Ryan Tammenoms Schwarz11
Steven Tammenoms Waite11
Julie Bakker11
Edward Tammenoms Peterson11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.